5 research outputs found
Receptor control of partial agonism at D<sub>2</sub>R with A135 mutations.
<p>(<b>A</b>) Relative proximity of G proteins (green spheres) and A135 (red sphere) in D3 (blue ribbon, PDB ID: 3PBL [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.ref037" target="_blank">37</a>]) as determined by alignment of D3R to β2AR in receptor/G protein complex (PDB ID: 3SN6, [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.ref038" target="_blank">38</a>]). (<b>B</b>) Arrestin (yellow spheres) does not reside close to A135 when D3R is aligned to rhodopsin in receptor/arrestin complex (PDB ID: 4ZWJ [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.ref039" target="_blank">39</a>]). (<b>C</b>) G protein activity as determined by inhibition of isoproterenol-induced cAMP accumulation is titrated by substitution of A135 with a bulky polar (tyrosine) or nonpolar (phenylalanine) residue and combined with L125N or M140D to impart controlled loss of G protein function. (<b>C</b>) β-arrestin 2 recruitment as determined by BRET is similarly controlled. All data are presented with SEM from n = 3–5 independent experiments, with statistical significance calculated in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.s003" target="_blank">S1 Table</a>.</p
Context dependent functional selectivity.
<p>(<b>A</b>) β-arrestin 2 recruitment comparing <sup>[WT]</sup>D<sub>2</sub>R and <sup>[IYIV]</sup>D<sub>2</sub>R as determined by bioluminescent resonance energy transfer (BRET). (<b>B</b>) GRK2 overexpression enhances β-arrestin 2 recruitment by BRET for <sup>[IYIV]</sup>D<sub>2</sub>R and <sup>[WT]</sup>D<sub>2</sub>R, but only slightly for <sup>[Gprot]</sup>D<sub>2</sub>R, <sup>[βarr]</sup>D<sub>2</sub>R, and <sup>[D80A]</sup>D<sub>2</sub>R when compared to [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.ref028" target="_blank">28</a>]. All data are presented with SEM from n = 3–4 independent experiments, with statistical significance calculated in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.s003" target="_blank">S1 Table</a>. Quantification of bias between G protein activity (data presented in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.s001" target="_blank">S1 Fig</a> and[<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.ref028" target="_blank">28</a>]) and β-arrestin 2 recruitment (data presented in Fig 1A and [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.ref028" target="_blank">28</a>]) using (<b>C</b>) a statistical formalism where K<sub>A</sub>, calculated from EC<sub>50</sub> = 1 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.ref033" target="_blank">33</a>] or (<b>D</b>) bias plot mapping under normal (solid lines) and GRK2 overexpression enhanced (broken lines) conditions.</p
Agonists and antagonists with diverse pharmacophores elicit predictable responses at <sup>[Gprot]</sup>D<sub>2</sub>R and <sup>[βarr]</sup>D<sub>2</sub>R.
<p>The D<sub>2</sub>R agonists quinpirole, apomorphine, and N-propylapomorphine (NPA) were tested for G protein activity (<b>A,C,E</b>) and β-arrestin 2 recruitment (<b>B,D,F</b>). For each agonist, <sup>[Gprot]</sup>D<sub>2</sub>R showed a response similar to <sup>[WT]</sup>D<sub>2</sub>R at G protein activation and more similar to <sup>[D80A]</sup>D<sub>2</sub>R for β-arrestin recruitment, while <sup>[βarr]</sup>D<sub>2</sub>R was not active at the G protein pathway but retained activity at the β-arrestin pathway. The antagonists raclopride (<b>G,H</b>) haloperidol (<b>I,J</b>) and partial antagonist aripiprazole (<b>K,L</b>) were able to block DA elicited D<sub>2</sub>R activation at the G protein pathway (<b>G,I,K</b>) for <sup>[Gprot]</sup>D<sub>2</sub>R and <sup>[WT]</sup>D<sub>2</sub>R to the same extent, while <sup>[D80A]</sup>D<sub>2</sub>R and <sup>[βarr]</sup>D<sub>2</sub>R had no effect to inhibit. In contrast, these antagonists block DA elicited β-arrestin 2 recruitment (<b>H,J,L</b>) for <sup>[βarr]</sup>D<sub>2</sub>R and <sup>[WT]</sup>D<sub>2</sub>R. All data are presented with SEM from n = 3–4 independent experiments, with statistical significance calculated in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.s005" target="_blank">S3 Table</a>.</p
Interacting partners and allosteric D<sub>2</sub>R determinants of functional selectivity.
<p>(<b>A</b>) GRK2 and (<b>B</b>) β-arrestin 1 recruitment as assessed by BRET show a similar profile as β-arrestin 2: <sup>[βarr]</sup>D<sub>2</sub>R recruits normally, while <sup>[Gprot]</sup>D<sub>2</sub>R is severely deficient. (<b>C</b>) Each D<sub>2</sub>R construct was expressed in HEK 293T cells and assessed for its ability to stimulate cAMP in response to DA. Stimulation of endogenous receptor by isoproterenol was used as a control response. (<b>D</b>) G<sub>αq</sub> mediated Ca<sup>2+</sup> flux, as measured by the aequorin luminescence assay, is not stimulated by <sup>[WT]</sup>D<sub>2</sub>R, <sup>[Gprot]</sup>D<sub>2</sub>R, <sup>[βarr]</sup>D<sub>2</sub>R or <sup>[D80A]</sup>D<sub>2</sub>R, compared to AngII induced Ca<sup>2+</sup> flux induced by transient expression of AT<sub>1A</sub>R. (<b>E</b>) B<sub>MAX</sub> was determined by binding, while luciferase-tagged receptors provided a B<sub>MAX</sub>-independent measure of receptor number. In this assay, the responsiveness to sodium is retained for all mutants (except <sup>[D80A]</sup>D<sub>2</sub>R). All data are presented with SEM from n = 3–4 independent experiments, with statistical significance calculated in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.s006" target="_blank">S4 Table</a>.</p
A unique G protein biased mutant demonstrates agonist texture.
<p>(<b>A</b>) Dopamine (DA) and quinpirole equivalently inhibit cAMP production, which is equivalent to <sup>[WT]</sup>D<sub>2</sub>R for <sup>[Gprot4PM]</sup>D<sub>2</sub>R (T69F Y133L Y209N A372S). (<b>B</b>) <sup>[Gprot4PM]</sup>D<sub>2</sub>R has roughly 50% efficacy in response to DA but not quinpirole for β-arrestin 2 recruitment. (<b>C</b>) GRK2 overexpression rescues both DA and quinpirole β-arrestin 2 recruitment activity nearly to <sup>[WT]</sup>D<sub>2</sub>R levels (dotted line, from <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.g001" target="_blank">Fig 1B</a>). (<b>D</b>) GRK2 recruitment as determined by BRET (where GRK2 is tagged with YFP) shows the same ligand discrepancy as β-arrestin 2. All data are presented with SEM from n = 3 independent experiments, with statistical significance calculated in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0141637#pone.0141637.s005" target="_blank">S3 Table</a>.</p